Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene

L. Poppova, S. Pavlova, B. Gonzalez, J. Kotaskova, K. Plevova, G. Dumbovic, P. Janovska, V. Bystry, A. Panovska, L. Bezdekova, S. Maslejova, Y. Brychtova, M. Doubek, M. Krzyzankova, M. Borsky, J. Mayer, V. Bryja, S. Alonso, S. Pospisilova

. 2022 ; 17 (12) : 1628-1635. [pub] 20220325

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032523

Genome methylation profiles define naïve-like (n-CLL), memory-like (m-CLL), and intermediate (i-CLL) subsets of chronic lymphocytic leukaemia (CLL). The profiles can be easily determined by the analysis of the five-CpG signature. m-CLL, i-CLL, and n-CLL with the good, intermediate, and poor prognoses, respectively, differ by the somatic hypermutation status of the immunoglobulin heavy chain variable gene (IGHV), a widely used prognostic predictor in CLL. We have previously shown that the expression of WNT5A, encoding a ROR1 ligand, distinguishes patients with the worse outcome within the prognostically favourable IGHV-mutated subgroup. To analyse the mechanisms controlling WNT5A expression, we investigated the methylation status of 54 CpG sites within the WNT5A promoter and its relation to the WNT5A gene expression. In a cohort of 59 CLL patients balanced for combinations of IGHV and WNT5A statuses, we identified three promoter CpG sites whose methylation level correlated with the WNT5A expression within the IGHV-mutated subgroup. Further, we complemented our data with the methylation status of the five-CpG signature. IGHV-mutated/WNT5A-negative and IGHV-mutated/WNT5A-positive cases overlapped with m‐CLL and i‐CLL methylation subgroups, respectively, while most IGHV‐unmutated samples were assigned to n-CLL. Median methylation levels of all the three CpG sites in the WNT5A promoter were lowest in i-CLL. Finally, a detailed analysis of m-CLL and i-CLL showed that undetectable WNT5A expression predicts longer treatment-free survival with higher statistical significance than the classification according to the five-CpG signature. To conclude, a favourable m-CLL subgroup is associated with mutated IGHV and undetectable WNT5A expression due to its promoter methylation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032523
003      
CZ-PrNML
005      
20230131151303.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/15592294.2022.2050004 $2 doi
035    __
$a (PubMed)35333703
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Poppova, Lucie $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
245    10
$a Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene / $c L. Poppova, S. Pavlova, B. Gonzalez, J. Kotaskova, K. Plevova, G. Dumbovic, P. Janovska, V. Bystry, A. Panovska, L. Bezdekova, S. Maslejova, Y. Brychtova, M. Doubek, M. Krzyzankova, M. Borsky, J. Mayer, V. Bryja, S. Alonso, S. Pospisilova
520    9_
$a Genome methylation profiles define naïve-like (n-CLL), memory-like (m-CLL), and intermediate (i-CLL) subsets of chronic lymphocytic leukaemia (CLL). The profiles can be easily determined by the analysis of the five-CpG signature. m-CLL, i-CLL, and n-CLL with the good, intermediate, and poor prognoses, respectively, differ by the somatic hypermutation status of the immunoglobulin heavy chain variable gene (IGHV), a widely used prognostic predictor in CLL. We have previously shown that the expression of WNT5A, encoding a ROR1 ligand, distinguishes patients with the worse outcome within the prognostically favourable IGHV-mutated subgroup. To analyse the mechanisms controlling WNT5A expression, we investigated the methylation status of 54 CpG sites within the WNT5A promoter and its relation to the WNT5A gene expression. In a cohort of 59 CLL patients balanced for combinations of IGHV and WNT5A statuses, we identified three promoter CpG sites whose methylation level correlated with the WNT5A expression within the IGHV-mutated subgroup. Further, we complemented our data with the methylation status of the five-CpG signature. IGHV-mutated/WNT5A-negative and IGHV-mutated/WNT5A-positive cases overlapped with m‐CLL and i‐CLL methylation subgroups, respectively, while most IGHV‐unmutated samples were assigned to n-CLL. Median methylation levels of all the three CpG sites in the WNT5A promoter were lowest in i-CLL. Finally, a detailed analysis of m-CLL and i-CLL showed that undetectable WNT5A expression predicts longer treatment-free survival with higher statistical significance than the classification according to the five-CpG signature. To conclude, a favourable m-CLL subgroup is associated with mutated IGHV and undetectable WNT5A expression due to its promoter methylation.
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x genetika $7 D015451
650    _2
$a těžké řetězce imunoglobulinů $x genetika $x metabolismus $7 D007143
650    _2
$a ligandy $7 D008024
650    _2
$a metylace DNA $7 D019175
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a prognóza $7 D011379
650    _2
$a mutace $7 D009154
650    _2
$a protein Wnt 5a $x genetika $x metabolismus $7 D000071818
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pavlova, Sarka $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000315289743
700    1_
$a Gonzalez, Beatriz $u IGTP-PMPPC: Program of Predictive and Personalized Medicine of Cancer, Germans Trias I Pujol Research Institute, Badalona, Spain $1 https://orcid.org/0000000236999392
700    1_
$a Kotaskova, Jana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000316727346
700    1_
$a Plevova, Karla $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $u Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000261488877
700    1_
$a Dumbovic, Gabrijela $u IGTP-PMPPC: Program of Predictive and Personalized Medicine of Cancer, Germans Trias I Pujol Research Institute, Badalona, Spain $u Institute for Cardiovascular Regeneration, Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany $1 https://orcid.org/0000000212780273
700    1_
$a Janovska, Pavlina $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000198710876
700    1_
$a Bystry, Vojtech $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000152780801
700    1_
$a Panovska, Anna $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000349553039
700    1_
$a Bezdekova, Lucie $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000221235226
700    1_
$a Maslejova, Stanislava $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Brychtova, Yvona $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000031038870X
700    1_
$a Doubek, Michael $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $u Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000212696282
700    1_
$a Krzyzankova, Marcela $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
700    1_
$a Borsky, Marek $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000158035941
700    1_
$a Mayer, Jiri $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000305679887
700    1_
$a Bryja, Vitezslav $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000291365085
700    1_
$a Alonso, Sergio $u IGTP-PMPPC: Program of Predictive and Personalized Medicine of Cancer, Germans Trias I Pujol Research Institute, Badalona, Spain $1 https://orcid.org/000000016497892X
700    1_
$a Pospisilova, Sarka $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $u Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000171362680
773    0_
$w MED00180218 $t Epigenetics $x 1559-2308 $g Roč. 17, č. 12 (2022), s. 1628-1635
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35333703 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151259 $b ABA008
999    __
$a ok $b bmc $g 1891344 $s 1183858
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 17 $c 12 $d 1628-1635 $e 20220325 $i 1559-2308 $m Epigenetics. $n Epigenetics $x MED00180218
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace